Patient Support Program Resources

PHONE
1-833-337-DUDE (1-833-337-3833)

FAX
1-844-NUBEQA3 (1-844-682-3723)

ONLINE
www.NUBEQAhcp.com

Information provided in this resource is for informational purposes only and does not guarantee that codes will be appropriate or that coverage and reimbursement will result. Customers should consult with their payers for all relevant coverage, coding, and reimbursement requirements. It is the sole responsibility of the provider to select proper codes and ensure the accuracy of all claims used in seeking reimbursement. Neither this resource nor DUDE Access Services™ is intended as legal advice or as a substitute for a provider’s independent professional judgment.
Prior Authorization Tips

Many health plans and prescription drug plans require Prior Authorization for drugs used to treat cancer, which means that the prescriber or patient may need to obtain authorization before NUBEQA® (darolutamide) can be reimbursed. Prior authorization criteria can vary by plan, so it is recommended to contact the plan directly to verify that all required information is submitted. Most plans will have a specific prior authorization request form to collect the required information. Provide complete and accurate information to avoid processing delays.

Here are some helpful tips to streamline the prior authorization process.

Include the following with every Prior Authorization request:

- Provider’s ID number (not the facility ID number) so the plan can identify the prescriber
- ICD-10-CM diagnosis code that most closely describes the patient’s diagnosis
- Name and National Drug Code (NDC) number for the drug

| 50419-395-01 | NUBEQA® (darolutamide) | 300 mg | Bottle of 120 tablets |

- Completed prescription form
- Photocopy of the patient’s insurance card
- Patient’s authorization of information release

Plans may also require supporting documentation, such as laboratory test results and the patient’s health history.

A letter of medical necessity may be required. If you need a sample letter of medical necessity, please contact your Bayer representative or download a template online at www.NUBEQAhcp.com

The provider’s office should call to verify that the health plan received the faxed or mailed submission and follow-up with the plan if a determination is not received within five business days.

INDICATION

NUBEQA® (darolutamide) tablets is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.

IMPORTANT SAFETY INFORMATION

Embryo-Fetal Toxicity: Safety and efficacy of NUBEQA have not been established in females. NUBEQA can cause fetal harm and loss of pregnancy. Advise males with female partners of reproductive potential to use effective contraception during treatment with NUBEQA and for 1 week after the last dose.

Please see additional Important Safety Information on the next page.
IMPORTANT SAFETY INFORMATION (continued)

Adverse Reactions

Serious adverse reactions occurred in 25% of patients receiving NUBEQA and in 20% of patients receiving placebo. Serious adverse reactions in ≥ 1% of patients who received NUBEQA were urinary retention, pneumonia, and hematuria. Overall, 3.9% of patients receiving NUBEQA and 3.2% of patients receiving placebo died from adverse reactions, which included death (0.4%), cardiac failure (0.3%), cardiac arrest (0.2%), general physical health deterioration (0.2%), and pulmonary embolism (0.2%) for NUBEQA.

Adverse reactions occurring more frequently in the NUBEQA arm (≥2% over placebo) were fatigue (16% vs. 11%), pain in extremity (6% vs. 3%) and rash (3% vs. 1%).

Clinically significant adverse reactions occurring in ≥ 2% of patients treated with NUBEQA included ischemic heart disease (4.0% vs. 3.4% on placebo) and heart failure (2.1% vs. 0.9% on placebo).

Drug Interactions

Effect of Other Drugs on NUBEQA – Concomitant use of NUBEQA with a combined P-gp and strong or moderate CYP3A4 inducer decreases darolutamide exposure, which may decrease NUBEQA activity. Avoid concomitant use of NUBEQA with combined P-gp and strong or moderate CYP3A4 inducers.

Concomitant use of NUBEQA with a combined P-gp and strong CYP3A4 inhibitor increases darolutamide exposure, which may increase the risk of NUBEQA adverse reactions. Monitor patients more frequently for NUBEQA adverse reactions and modify NUBEQA dosage as needed.

Effects of NUBEQA on Other Drugs – NUBEQA is an inhibitor of breast cancer resistance protein (BCRP) transporter. Concomitant use of NUBEQA increases the exposure (AUC) and maximal concentration of BCRP substrates, which may increase the risk of BCRP substrate-related toxicities. Avoid concomitant use with drugs that are BCRP substrates where possible. If used together, monitor patients more frequently for adverse reactions, and consider dose reduction of the BCRP substrate drug. Consult the approved product labeling of the BCRP substrate when used concomitantly with NUBEQA.

Please see additional Important Safety Information on the previous page, and click here for the full Prescribing Information.